Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 6/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634177 | 0.78 | — | — | |
| SCHEMBL6047662 | 0.76 | SLC6A4 (0.34) | KMT2A | |
| SCHEMBL5887552 | 0.74 | MAOB (0.35) | KMT2A | |
| SCHEMBL7373252 | 0.70 | TDP1 (0.35) | PDE4B | |
| SCHEMBL18704291 | 0.69 | — | — | |
| SCHEMBL4806239 | 0.68 | TSHR (0.32) | — | |
| SCHEMBL4807473 | 0.68 | — | — | |
| SCHEMBL4697710 | 0.68 | PDE4D (0.36) | PDE4APDE4BPDE4DMAPK14PDE4C | |
| SCHEMBL5318359 | 0.66 | — | — | |
| SCHEMBL4019693 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| EP-1796602-A2 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | Angiotech Pharmaceuticals (US), Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006083260-A2 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIOTECH BIOMATERIALS CORPORATION (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006078282-A2 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIOTECH BIOMATERIALS CORPORATION (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006034128-A2 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH BIOMATERIALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-0819122-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996031485-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-10-10 | — | — | WO | disclosed |
| WO-1995027692-A1 | SUBTITUTED BIPHENYL TNF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |